

KidneyCompanion

Advanced AI Medical Analysis Report

Patient Information

Name: Aditya Yogesh Raje

Age: 55

Address: F-104,TARANGANA RESIDENCY,NEAR KHUBWAJYODHAWK, HARPALE WASTI,PHURSUNGI,HADAPS

Phone Number: 09699616876

Medications & Dosage

#	Medication Name	Dosage	Frequency	Notes
1	Lisinopril	1-0-1	3days	

Clinical Insights

- Lisinopril is an Angiotensin-Converting Enzyme (ACE) inhibitor commonly prescribed for conditions such as hypertension, heart failure, and post-myocardial infarction. It is also frequently used in patients with chronic kidney disease (CKD) for its renoprotective effects, particularly in those with proteinuria, as it can help reduce intraglomerular pressure and slow disease progression. However, the provided patient profile lacks crucial information such as CKD stage, eGFR, serum creatinine, potassium, and blood pressure readings. While the profile indicates 'Has Hypertension: 0', Lisinopril may be prescribed for other indications not specified, or for renoprotection in early CKD. The short duration of '3 days' is unusual for chronic Lisinopril therapy and might represent an initial trial period or an incomplete prescription detail. Without baseline kidney function and electrolyte levels, a precise assessment of its appropriateness and dosing for this individual is limited.

Risk Assessment

- Initiation of Lisinopril, especially in patients with unknown kidney function, carries several potential risks. These include acute kidney injury (AKI), particularly if there is underlying renal artery stenosis or significant volume depletion. Hyperkalemia is another significant risk, as ACE inhibitors can reduce aldosterone secretion, leading to potassium retention. Hypotension (low blood pressure) is common, especially with the first dose. Other potential side effects include a persistent dry cough and angioedema (swelling of the face, lips, tongue, or throat), which can be life-threatening. Given the lack of baseline eGFR, serum creatinine, and potassium levels, these risks are heightened and require

KidneyCompanion

Advanced AI Medical Analysis Report

careful monitoring.

Lifestyle & Care Recommendations

- Before initiating or continuing Lisinopril, it is generally recommended to obtain baseline measurements of eGFR, serum creatinine, and serum potassium. Blood pressure should also be monitored regularly, especially after the first dose and any dose adjustments. Patients should be educated on the symptoms of hypotension (dizziness, lightheadedness), hyperkalemia (muscle weakness, fatigue), and angioedema (swelling). Hydration status should be assessed, and concurrent use of NSAIDs or potassium-sparing diuretics should be reviewed.

Potential Drug Interactions

- Common drug interactions with Lisinopril include:
- Potassium-sparing diuretics (e.g., spironolactone, amiloride) and potassium supplements, which can increase the risk of hyperkalemia.
- Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen, which can reduce the antihypertensive effect of Lisinopril and increase the risk of renal dysfunction.
- Lithium, as Lisinopril can increase serum lithium levels, potentially leading to toxicity.
- Other antihypertensive medications, which may potentiate the hypotensive effect.
- Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) with an Angiotensin Receptor Blocker (ARB) or direct renin inhibitor (e.g., aliskiren) is generally not recommended due to increased risks of hypotension, hyperkalemia, and renal impairment.

Recommended Follow-up

- For new initiation of Lisinopril, especially in patients with potential CKD or unknown kidney function, a follow-up visit is typically recommended within 1-2 weeks. This visit should include repeat measurements of serum creatinine, eGFR, and serum potassium to assess for changes in kidney function and electrolyte balance. Blood pressure should also be re-evaluated to ensure efficacy and rule out excessive hypotension. Further follow-up frequency would depend on the patient's response, stability of lab values, and overall clinical condition.

MEDICAL DISCLAIMER

KidneyCompanion

Advanced AI Medical Analysis Report

This analysis does NOT constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.